Recent research have converged on the overlap of glucagon-like peptide-1|GIP|glucagon receptor agonist therapies and DA signaling. While GCGR agonists are widely employed for addressing type 2 T2DM, their potential effects on motivation circuits, specifically influenced by dopamine networks, are gaining significant interest. This report provides a